Patents by Inventor Jonathan F. Smith

Jonathan F. Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10570416
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: February 25, 2020
    Assignee: ALPHAVAX, INC.
    Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
  • Patent number: 10434187
    Abstract: Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector of replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: October 8, 2019
    Assignee: APHAVAX, INC.
    Inventors: Vernon McNeil Coffield, III, Kurt I. Kamrud, Jonathan F. Smith
  • Patent number: 10111943
    Abstract: The immune response to an antigen of interest, especially one in purified form, can be significantly enhanced by the simultaneous administration of an alphavirus replicon particle which expresses the same antigen. This allows for the use of significantly smaller quantities of the protein antigen than in conventional immunization strategies, and this new immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: October 30, 2018
    Assignee: ALPHAVAX, INC.
    Inventors: Jonathan F. Smith, Bolyn Hubby, Laura Copp
  • Publication number: 20180050118
    Abstract: Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector of replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided.
    Type: Application
    Filed: March 15, 2017
    Publication date: February 22, 2018
    Inventors: Vernon McNeil COFFIELD, III, Kurt I. KAMRUD, Jonathan F. SMITH
  • Patent number: 9597414
    Abstract: Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector or replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: March 21, 2017
    Assignee: ALPHAVAX, INC.
    Inventors: Vernon McNeil Coffield, III, Kurt I. Kamrud, Jonathan F. Smith
  • Publication number: 20160375124
    Abstract: The immune response to an antigen of interest, especially one in purified form, can be significantly enhanced by the simultaneous administration of an alphavirus replicon particle which expresses the same antigen. This allows for the use of significantly smaller quantities of the protein antigen than in conventional immunization strategies, and this new immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.
    Type: Application
    Filed: June 29, 2016
    Publication date: December 29, 2016
    Inventors: Jonathan F. SMITH, Bolyn Hubby, Laura Copp
  • Publication number: 20160348132
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Application
    Filed: August 11, 2016
    Publication date: December 1, 2016
    Inventors: Jon O. RAYNER, Jonathan F. SMITH, Bolyn HUBBY, Elizabeth A. REAP
  • Patent number: 9441247
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: September 13, 2016
    Assignee: ALPHAVAX, INC.
    Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
  • Patent number: 9416370
    Abstract: The immune response to an antigen of interest, especially one in purified form, can be significantly enhanced by the simultaneous administration of an alphavirus replicon particle which expresses the same antigen. This allows for the use of significantly smaller quantities of the protein antigen than in conventional immunization strategies, and this new immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: August 16, 2016
    Assignee: AlphaVax, Inc.
    Inventors: Jonathan F. Smith, Bolyn Hubby, Laura Copp
  • Publication number: 20150299728
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Application
    Filed: July 6, 2015
    Publication date: October 22, 2015
    Inventors: Jon O. RAYNER, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
  • Patent number: 9079943
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: July 14, 2015
    Assignee: ALPHAVAX, INC.
    Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
  • Publication number: 20140308312
    Abstract: Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector or replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided.
    Type: Application
    Filed: February 5, 2014
    Publication date: October 16, 2014
    Applicant: ALPHAVAX, INC.
    Inventors: Vernon McNeil Coffield, III, Kurt I. Kamrud, Jonathan F. Smith
  • Publication number: 20140205629
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Application
    Filed: March 28, 2014
    Publication date: July 24, 2014
    Applicant: AlphaVax, Inc.
    Inventors: Jon O. RAYNER, Jonathan F. SMITH, Bolyn HUBBY, Elizabeth A. REAP
  • Patent number: 8709441
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: April 29, 2014
    Assignee: Alphavax, Inc.
    Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
  • Patent number: 8680258
    Abstract: Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector or replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: March 25, 2014
    Assignee: Alphavax, Inc.
    Inventors: Vernon McNeil Coffield, Kurt I. Kamrud, Jonathan F. Smith
  • Patent number: 8617533
    Abstract: Viral replicon selected nucleic acid expression libraries are useful for analyzing multiple antigens associated with a parasite, pathogen or neoplasia or for preparing immunogenic compositions for generating immune responses specific for the parasite, pathogen or neoplasia. Alphavirus replicon particles representative of the nucleic acid expression library are preferred. The nucleic acid library can be a random library, or it can be prepared after a selection step, for example, by differential hybridization prior to cloning into the replicon vector.
    Type: Grant
    Filed: May 6, 2008
    Date of Patent: December 31, 2013
    Assignee: AlphaVax, Inc.
    Inventors: Jonathan F. Smith, Kurt Kamrud, Sergey Dryga, Ian Caley
  • Patent number: 8460913
    Abstract: The present invention provides an isolated RNA molecule comprising: a) an alphavirus 5? replication recognition sequence, wherein at least one initiation codon has been removed from the 5? replication recognition sequence; b) a nucleotide sequence encoding an alphavirus structural protein; and c) an alphavirus 3? replication recognition sequence, with the proviso that the RNA molecule does not contain a promoter that directs transcription of the nucleotide sequence of (b), and wherein the alphavirus 5? and 3? replication recognition sequences of (a) and (c) direct replication of the RNA molecule in the presence of alphavirus non-structural proteins.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: June 11, 2013
    Assignee: Alpha Vax, Inc.
    Inventors: Kurt I. Kamrud, Jonathan F. Smith, Maureen Maughan
  • Patent number: 8263092
    Abstract: The immune response to an antigen of interest, either in purified form or expressed via an alphavirus replicon particle, can be enhanced by the simultaneous administration of an alphavirus replicon particle which expresses interleukin-12. This allows for the use of significantly smaller quantities of the antigen and this immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.
    Type: Grant
    Filed: September 12, 2007
    Date of Patent: September 11, 2012
    Assignee: AlphaVax, Inc.
    Inventors: Jonathan F. Smith, Bolyn Hubby, Peter Berglund, Laura Copp, Whitney Ellis
  • Publication number: 20120213813
    Abstract: The immune response to an antigen of interest, either in purified form or expressed via an alphavirus replicon particle, can be enhanced by the simultaneous administration of an alphavirus replicon particle which expresses interleukin-12. This allows for the use of significantly smaller quantities of the antigen and this immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.
    Type: Application
    Filed: September 12, 2007
    Publication date: August 23, 2012
    Applicant: AlphaVax, Inc.
    Inventors: Jonathan F. Smith, Bolyn Hubby, Peter Berglund, Laura Copp, Whitney Ellis
  • Publication number: 20120100179
    Abstract: Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector or replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided.
    Type: Application
    Filed: November 25, 2009
    Publication date: April 26, 2012
    Applicant: ALPHAVAX, INC.
    Inventors: Vernon McNeil Coffield, Kurt I. Kamrud, Jonathan F. Smith